A Comparative Study of Serum HDL, Serum Creatinine and Serum C-reactive protein in assessing severity of sepsis.
Not Applicable
- Conditions
- Health Condition 1: A00-B99- Certain infectious and parasitic diseases
- Registration Number
- CTRI/2024/02/062309
- Lead Sponsor
- Calcutta National Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with age greater than 18 years and satisfying the criteria for sepsis according to International guidelines for management of severe sepsis and septic shock.
Exclusion Criteria
1. Patients on treatment with statins.
2. Patients with chronic kidney disease, chronic liver disease, thyroid dysfunction, diabetes mellitus, and malabsorption disorders.
3. Patients with known chronic infective and inflammatory conditions like Human immunodeficiency virus disease, SLE(Systemic lupus erythematous) and RA( Rheumatoid arthritis)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The SOFA Score of patients who survives will be low and those who do not survive the score <br/ ><br>will be high. The three parameters may show the following outcomes: <br/ ><br>(i)The serum HDL-cholesterol values may be low in non survivors and may be high or within <br/ ><br>normal limits among the survivors. <br/ ><br>(ii)The serum CRP values are likely to be high among the non survivors and low among the <br/ ><br>non survivors. <br/ ><br>(iii)The serum creatinine levels are likely to be high in patients who will be progressing <br/ ><br>towards septic shock and MODS and finally death.Timepoint: Twelve months
- Secondary Outcome Measures
Name Time Method All the three parameters in this study i.e. serum HDL, serum Creatinine, serum C- reactive protein will help in determining the disease progression in the <br/ ><br>patient so that prompt action can be taken in appropriate time to alter the course of disease <br/ ><br>with treatment modifications if possible, depending upon the patient’s clinical condition.Timepoint: Twelve months.